2005 Annual Meeting | Frontiers In Clinical Neuroscience Plenary Session
| 09:00 AM - 09:05 AM |
Introduction to Frontiers Plenary Session
John W. Griffin, MD |
|
| 09:00 AM - 11:00 AM |
Break
|
|
| 09:05 AM - 09:30 AM |
RNA-Mediated Neurological Diseases
Charles A. Thornton, MD, FAAN |
|
| 09:30 AM - 10:00 AM |
Harnessing the Neuroprotective Power of the Brain
Valina Dawson, PhD |
|
| 10:00 AM - 10:30 AM |
Cognitive Dysfunction in Schizophrenia: Pathophysiological Mechanisms and Treatment Interventions
David A. Lewis, MD |
|
| 10:30 AM - 11:00 AM |
Finding the Causes of Inherited Neuropathies
Steven Scherer, MD |
| Charles A. Thornton, MD, FAAN | Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avidity. Dr. Thornton has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Thornton has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ionis. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne. Dr. Thornton has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Pepgen. The institution of Dr. Thornton has received research support from Marigold Foundation. The institution of Dr. Thornton has received research support from NIH. The institution of Dr. Thornton has received research support from Muscular Dystrophy Association . The institution of Dr. Thornton has received research support from Dyne. The institution of Dr. Thornton has received research support from Avidity. The institution of Dr. Thornton has received research support from Ionis. Dr. Thornton has received intellectual property interests from a discovery or technology relating to health care. |
| John W. Griffin, MD | No disclosure on file |
| Steven Scherer, MD | Dr. Scherer has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Pfizer. Dr. Scherer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Scherer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Toray Industries. Dr. Scherer has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Applied Therapeutics. Dr. Scherer has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Disarm Therapeutics. Dr. Scherer has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Mitochondria in Motion. The institution of Dr. Scherer has received research support from NIH . |
| David A. Lewis, MD | No disclosure on file |
| Valina Dawson, PhD | Dr. Dawson has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Valted Seq Inc. An immediate family member of Dr. Dawson has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Valted Seq Inc. Dr. Dawson has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for eNeuro. Dr. Dawson has stock in Valted Seq Inc. An immediate family member of Dr. Dawson has stock in Valted Seq Inc. Dr. Dawson has stock in D&D Pharmatech. An immediate family member of Dr. Dawson has stock in D&D Pharmatech. Dr. Dawson has stock in Inhibikase Therapeutics, Inc. An immediate family member of Dr. Dawson has stock in Inhibikase Therapeutics, Inc,. An immediate family member of Dr. Dawson has stock in American Gene Technologies International. An immediate family member of Dr. Dawson has stock in Abbvie. The institution of an immediate family member of Dr. Dawson has received research support from Sun Pharmaceutical Industries Ltd. The institution of an immediate family member of Dr. Dawson has received research support from Sebum. Dr. Dawson has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dawson has received intellectual property interests from a discovery or technology relating to health care. An immediate family member of Dr. Dawson has received personal compensation in the range of $100,000-$499,999 for serving as a Advisor with Mitokini. |